Compare OCSL & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OCSL | SLS |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 924.5M |
| IPO Year | 2007 | 2007 |
| Metric | OCSL | SLS |
|---|---|---|
| Price | $11.69 | $12.39 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $12.63 | $10.00 |
| AVG Volume (30 Days) | 578.4K | ★ 7.9M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | ★ 12.73% | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.31 | $110.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.63 | $1.39 |
| 52 Week High | $14.77 | $11.06 |
| Indicator | OCSL | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 45.19 | 77.80 |
| Support Level | $11.01 | $3.72 |
| Resistance Level | $12.26 | N/A |
| Average True Range (ATR) | 0.26 | 0.80 |
| MACD | -0.03 | 0.29 |
| Stochastic Oscillator | 34.93 | 96.23 |
Oaktree Specialty Lending Corp is a specialty finance company. The company provides lending services and invests in small and mid-sized companies. The company's investment objective is to maximize its portfolio's total return by generating current income from debt investments, and to a lesser extent, capital appreciation from equity investments. The company provides customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets. The company operates as a single reportable segment and derives revenues from investing in originated loans and other securities, including broadly syndicated loans, of U.S. private companies and manages the business on a consolidated basis.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.